Graham K. Cooper - Jul 24, 2023 Form 4 Insider Report for Kezar Life Sciences, Inc. (KZR)

Role
Director
Signature
/s/ Marc Belsky, Attorney-in-Fact
Stock symbol
KZR
Transactions as of
Jul 24, 2023
Transactions value $
$0
Form type
4
Date filed
7/26/2023, 04:57 PM
Previous filing
Jun 16, 2023
Next filing
Jun 7, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KZR Stock Option (Right to Buy) Disposed to Issuer -8.9K -100% 0 Jul 24, 2023 Common Stock 8.9K $7.63 Direct F1, F2
transaction KZR Stock Option (Right to Buy) Award +8.9K 8.9K Jul 24, 2023 Common Stock 8.9K $2.28 Direct F1, F2
transaction KZR Stock Option (Right to Buy) Disposed to Issuer -8.9K -100% 0 Jul 24, 2023 Common Stock 8.9K $5.60 Direct F1, F2
transaction KZR Stock Option (Right to Buy) Award +8.9K 8.9K Jul 24, 2023 Common Stock 8.9K $2.28 Direct F1, F2
transaction KZR Stock Option (Right to Buy) Disposed to Issuer -26K -100% 0 Jul 24, 2023 Common Stock 26K $5.59 Direct F1, F2
transaction KZR Stock Option (Right to Buy) Award +26K 26K Jul 24, 2023 Common Stock 26K $2.28 Direct F1, F2
transaction KZR Stock Option (Right to Buy) Disposed to Issuer -26K -100% 0 Jul 24, 2023 Common Stock 26K $5.52 Direct F2, F3
transaction KZR Stock Option (Right to Buy) Award +26K 26K Jul 24, 2023 Common Stock 26K $2.28 Direct F2, F3
transaction KZR Stock Option (Right to Buy) Disposed to Issuer -26K -100% 0 Jul 24, 2023 Common Stock 26K $4.80 Direct F1, F2
transaction KZR Stock Option (Right to Buy) Award +26K 26K Jul 24, 2023 Common Stock 26K $2.28 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested and exercisable.
F2 On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.
F3 One thirty-sixth (1/36th) of the shares vested or shall vest on a monthly basis commencing on May 12, 2022, subject to the Reporting Person continuing to provide service through each such date.